Rotavirus specific maternal antibodies and immune response to RV3-BB rotavirus vaccine in central java and yogyakarta, Indonesia
•IgA in breast milk was not associated with reduced RV3-BB vaccine take in Indonesia.•IgG titre in cord blood was associated with lower vaccine immunogenicity after one, not three doses of vaccine.•RV3-BB vaccine appears to be able to be given with breast-feeding in high rotavirus disease burden set...
Gespeichert in:
| Veröffentlicht in: | Vaccine 2020-04, Vol.38 (16), p.3235-3242 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 3242 |
|---|---|
| container_issue | 16 |
| container_start_page | 3235 |
| container_title | Vaccine |
| container_volume | 38 |
| creator | Danchin, Margie H. Bines, Julie E. Watts, Emma Cowley, Daniel Pavlic, Daniel Lee, Katherine J. Huque, Hamidul Kirkwood, Carl Nirwati, Hera At thobari, Jarir Dewi Satria, Cahya Soenarto, Yati Oktaria, Vicka |
| description | •IgA in breast milk was not associated with reduced RV3-BB vaccine take in Indonesia.•IgG titre in cord blood was associated with lower vaccine immunogenicity after one, not three doses of vaccine.•RV3-BB vaccine appears to be able to be given with breast-feeding in high rotavirus disease burden settings.
Placental or breast milk maternal antibodies can potentially reduce oral rotavirus vaccine efficacy in developing countries. We aimed to examine the relationship between the level of rotavirus specific immunoglobulin A (IgA) and neutralising antibodies (NA) in colostrum and breast milk and cord IgG, with cumulative vaccine take following one and three doses of oral RV3-BB rotavirus vaccine within a Phase IIb trial in Indonesia.
196 infants received three doses of RV3-BB in a randomized, double-blinded trial, using a neonatal schedule (first dose at 0–5 days of age, n = 61), an infant schedule (first dose at ~ 8 weeks of age, n = 67) or placebo (n = 68). Rotavirus specific IgA and NA in colostrum and breast milk, rotavirus specific cord IgG, Serum IgA and stool excretion were measured.
There was little evidence of an association between IgA in colostrum or breast milk and cumulative vaccine take after three doses in the neonatal or infant groups. In the neonatal group, there was a negative association between IgG titre in cord blood and cumulative vaccine take (odds ratio [OR] 0.96; 95% confidence interval [CI] 0.92–1.00; p = 0.03) and serum IgA response (OR 0.94; 95%CI 0.89–0.99; p = 0.02) after one dose of vaccine, which were not evident after three doses in the neonatal or infant groups.
Amongst Indonesian infants we did not find an association between IgA in colostrum or breast milk and vaccine take after 3 doses of RV3-BB vaccine. Maternal rotavirus antibodies in breast milk appear to have minimal impact on RV3-BB vaccine take when administered with a short delay in breast-feeding in settings with a high rotavirus disease burden. |
| doi_str_mv | 10.1016/j.vaccine.2020.02.087 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2376732488</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X20303340</els_id><sourcerecordid>2425690885</sourcerecordid><originalsourceid>FETCH-LOGICAL-c393t-a12d966a961e3a5f0de398f43e2164f3ac303694338220e7931d8527315865eb3</originalsourceid><addsrcrecordid>eNqFkUFv1DAQhS0EokvhJ4AsceFAgu1JHOeE2opCpUpIFSBulteZIIeNvdjOSnvjp-PtLj1w4eQ5fO-N5z1CXnJWc8blu6neGWudx1owwWomaqa6R2TFVQeVaLl6TFZMyKZqOPt-Rp6lNDHGWuD9U3IGgkvWN2pFft-FbHYuLommLVo3OktnkzF6s6HGZ7cOg8NUxoG6eV480ohpG3xCmgO9-wbV5SWNDyanT1HnqUWfY3GZzM7c6_fhx978NDGbt_TGD8FjcuY5eTKaTcIXp_ecfL3-8OXqU3X7-ePN1cVtZaGHXBkuhl5K00uOYNqRDQi9GhvAckozgrHAQPYNgBKCYdcDH1QrOuCtki2u4Zy8OfpuY_i1YMp6dsniZmM8hiVpAZ3sQDRKFfT1P-gUlkMghWpEK3umVFuo9kjZGFKKOOptdLOJe82ZPlSkJ31KQx8q0kzoUlHRvTq5L-sZhwfV304K8P4IYIlj5zDqZB16i4OLaLMegvvPij_csKSY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2425690885</pqid></control><display><type>article</type><title>Rotavirus specific maternal antibodies and immune response to RV3-BB rotavirus vaccine in central java and yogyakarta, Indonesia</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><source>ProQuest Central UK/Ireland</source><creator>Danchin, Margie H. ; Bines, Julie E. ; Watts, Emma ; Cowley, Daniel ; Pavlic, Daniel ; Lee, Katherine J. ; Huque, Hamidul ; Kirkwood, Carl ; Nirwati, Hera ; At thobari, Jarir ; Dewi Satria, Cahya ; Soenarto, Yati ; Oktaria, Vicka</creator><creatorcontrib>Danchin, Margie H. ; Bines, Julie E. ; Watts, Emma ; Cowley, Daniel ; Pavlic, Daniel ; Lee, Katherine J. ; Huque, Hamidul ; Kirkwood, Carl ; Nirwati, Hera ; At thobari, Jarir ; Dewi Satria, Cahya ; Soenarto, Yati ; Oktaria, Vicka</creatorcontrib><description>•IgA in breast milk was not associated with reduced RV3-BB vaccine take in Indonesia.•IgG titre in cord blood was associated with lower vaccine immunogenicity after one, not three doses of vaccine.•RV3-BB vaccine appears to be able to be given with breast-feeding in high rotavirus disease burden settings.
Placental or breast milk maternal antibodies can potentially reduce oral rotavirus vaccine efficacy in developing countries. We aimed to examine the relationship between the level of rotavirus specific immunoglobulin A (IgA) and neutralising antibodies (NA) in colostrum and breast milk and cord IgG, with cumulative vaccine take following one and three doses of oral RV3-BB rotavirus vaccine within a Phase IIb trial in Indonesia.
196 infants received three doses of RV3-BB in a randomized, double-blinded trial, using a neonatal schedule (first dose at 0–5 days of age, n = 61), an infant schedule (first dose at ~ 8 weeks of age, n = 67) or placebo (n = 68). Rotavirus specific IgA and NA in colostrum and breast milk, rotavirus specific cord IgG, Serum IgA and stool excretion were measured.
There was little evidence of an association between IgA in colostrum or breast milk and cumulative vaccine take after three doses in the neonatal or infant groups. In the neonatal group, there was a negative association between IgG titre in cord blood and cumulative vaccine take (odds ratio [OR] 0.96; 95% confidence interval [CI] 0.92–1.00; p = 0.03) and serum IgA response (OR 0.94; 95%CI 0.89–0.99; p = 0.02) after one dose of vaccine, which were not evident after three doses in the neonatal or infant groups.
Amongst Indonesian infants we did not find an association between IgA in colostrum or breast milk and vaccine take after 3 doses of RV3-BB vaccine. Maternal rotavirus antibodies in breast milk appear to have minimal impact on RV3-BB vaccine take when administered with a short delay in breast-feeding in settings with a high rotavirus disease burden.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2020.02.087</identifier><identifier>PMID: 32160948</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Aged ; Antibodies ; Antibodies, Viral ; Breast ; Breast milk ; Breastfeeding & lactation ; Clinical trials ; Colostrum ; Confidence intervals ; Cord blood ; Developing countries ; Efficacy ; Ethics ; Female ; Humans ; Immune response ; Immune system ; Immunity ; Immunoglobulin A ; Immunoglobulin G ; Indonesia - epidemiology ; Infant ; Infants ; Laboratories ; LDCs ; Low income groups ; Maternal antibodies ; Middle Aged ; Milk ; Neonates ; Placenta ; Pregnancy ; Questionnaires ; Regression analysis ; Rotavirus ; Rotavirus Infections - prevention & control ; Rotavirus Vaccines ; Schedules ; Vaccine efficacy ; Vaccines ; Viruses</subject><ispartof>Vaccine, 2020-04, Vol.38 (16), p.3235-3242</ispartof><rights>2020 Elsevier Ltd</rights><rights>Copyright © 2020 Elsevier Ltd. All rights reserved.</rights><rights>2020. Elsevier Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c393t-a12d966a961e3a5f0de398f43e2164f3ac303694338220e7931d8527315865eb3</citedby><cites>FETCH-LOGICAL-c393t-a12d966a961e3a5f0de398f43e2164f3ac303694338220e7931d8527315865eb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/2425690885?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,777,781,3537,27905,27906,45976,64364,64366,64368,72218</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32160948$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Danchin, Margie H.</creatorcontrib><creatorcontrib>Bines, Julie E.</creatorcontrib><creatorcontrib>Watts, Emma</creatorcontrib><creatorcontrib>Cowley, Daniel</creatorcontrib><creatorcontrib>Pavlic, Daniel</creatorcontrib><creatorcontrib>Lee, Katherine J.</creatorcontrib><creatorcontrib>Huque, Hamidul</creatorcontrib><creatorcontrib>Kirkwood, Carl</creatorcontrib><creatorcontrib>Nirwati, Hera</creatorcontrib><creatorcontrib>At thobari, Jarir</creatorcontrib><creatorcontrib>Dewi Satria, Cahya</creatorcontrib><creatorcontrib>Soenarto, Yati</creatorcontrib><creatorcontrib>Oktaria, Vicka</creatorcontrib><title>Rotavirus specific maternal antibodies and immune response to RV3-BB rotavirus vaccine in central java and yogyakarta, Indonesia</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>•IgA in breast milk was not associated with reduced RV3-BB vaccine take in Indonesia.•IgG titre in cord blood was associated with lower vaccine immunogenicity after one, not three doses of vaccine.•RV3-BB vaccine appears to be able to be given with breast-feeding in high rotavirus disease burden settings.
Placental or breast milk maternal antibodies can potentially reduce oral rotavirus vaccine efficacy in developing countries. We aimed to examine the relationship between the level of rotavirus specific immunoglobulin A (IgA) and neutralising antibodies (NA) in colostrum and breast milk and cord IgG, with cumulative vaccine take following one and three doses of oral RV3-BB rotavirus vaccine within a Phase IIb trial in Indonesia.
196 infants received three doses of RV3-BB in a randomized, double-blinded trial, using a neonatal schedule (first dose at 0–5 days of age, n = 61), an infant schedule (first dose at ~ 8 weeks of age, n = 67) or placebo (n = 68). Rotavirus specific IgA and NA in colostrum and breast milk, rotavirus specific cord IgG, Serum IgA and stool excretion were measured.
There was little evidence of an association between IgA in colostrum or breast milk and cumulative vaccine take after three doses in the neonatal or infant groups. In the neonatal group, there was a negative association between IgG titre in cord blood and cumulative vaccine take (odds ratio [OR] 0.96; 95% confidence interval [CI] 0.92–1.00; p = 0.03) and serum IgA response (OR 0.94; 95%CI 0.89–0.99; p = 0.02) after one dose of vaccine, which were not evident after three doses in the neonatal or infant groups.
Amongst Indonesian infants we did not find an association between IgA in colostrum or breast milk and vaccine take after 3 doses of RV3-BB vaccine. Maternal rotavirus antibodies in breast milk appear to have minimal impact on RV3-BB vaccine take when administered with a short delay in breast-feeding in settings with a high rotavirus disease burden.</description><subject>Aged</subject><subject>Antibodies</subject><subject>Antibodies, Viral</subject><subject>Breast</subject><subject>Breast milk</subject><subject>Breastfeeding & lactation</subject><subject>Clinical trials</subject><subject>Colostrum</subject><subject>Confidence intervals</subject><subject>Cord blood</subject><subject>Developing countries</subject><subject>Efficacy</subject><subject>Ethics</subject><subject>Female</subject><subject>Humans</subject><subject>Immune response</subject><subject>Immune system</subject><subject>Immunity</subject><subject>Immunoglobulin A</subject><subject>Immunoglobulin G</subject><subject>Indonesia - epidemiology</subject><subject>Infant</subject><subject>Infants</subject><subject>Laboratories</subject><subject>LDCs</subject><subject>Low income groups</subject><subject>Maternal antibodies</subject><subject>Middle Aged</subject><subject>Milk</subject><subject>Neonates</subject><subject>Placenta</subject><subject>Pregnancy</subject><subject>Questionnaires</subject><subject>Regression analysis</subject><subject>Rotavirus</subject><subject>Rotavirus Infections - prevention & control</subject><subject>Rotavirus Vaccines</subject><subject>Schedules</subject><subject>Vaccine efficacy</subject><subject>Vaccines</subject><subject>Viruses</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkUFv1DAQhS0EokvhJ4AsceFAgu1JHOeE2opCpUpIFSBulteZIIeNvdjOSnvjp-PtLj1w4eQ5fO-N5z1CXnJWc8blu6neGWudx1owwWomaqa6R2TFVQeVaLl6TFZMyKZqOPt-Rp6lNDHGWuD9U3IGgkvWN2pFft-FbHYuLommLVo3OktnkzF6s6HGZ7cOg8NUxoG6eV480ohpG3xCmgO9-wbV5SWNDyanT1HnqUWfY3GZzM7c6_fhx978NDGbt_TGD8FjcuY5eTKaTcIXp_ecfL3-8OXqU3X7-ePN1cVtZaGHXBkuhl5K00uOYNqRDQi9GhvAckozgrHAQPYNgBKCYdcDH1QrOuCtki2u4Zy8OfpuY_i1YMp6dsniZmM8hiVpAZ3sQDRKFfT1P-gUlkMghWpEK3umVFuo9kjZGFKKOOptdLOJe82ZPlSkJ31KQx8q0kzoUlHRvTq5L-sZhwfV304K8P4IYIlj5zDqZB16i4OLaLMegvvPij_csKSY</recordid><startdate>20200403</startdate><enddate>20200403</enddate><creator>Danchin, Margie H.</creator><creator>Bines, Julie E.</creator><creator>Watts, Emma</creator><creator>Cowley, Daniel</creator><creator>Pavlic, Daniel</creator><creator>Lee, Katherine J.</creator><creator>Huque, Hamidul</creator><creator>Kirkwood, Carl</creator><creator>Nirwati, Hera</creator><creator>At thobari, Jarir</creator><creator>Dewi Satria, Cahya</creator><creator>Soenarto, Yati</creator><creator>Oktaria, Vicka</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20200403</creationdate><title>Rotavirus specific maternal antibodies and immune response to RV3-BB rotavirus vaccine in central java and yogyakarta, Indonesia</title><author>Danchin, Margie H. ; Bines, Julie E. ; Watts, Emma ; Cowley, Daniel ; Pavlic, Daniel ; Lee, Katherine J. ; Huque, Hamidul ; Kirkwood, Carl ; Nirwati, Hera ; At thobari, Jarir ; Dewi Satria, Cahya ; Soenarto, Yati ; Oktaria, Vicka</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c393t-a12d966a961e3a5f0de398f43e2164f3ac303694338220e7931d8527315865eb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Aged</topic><topic>Antibodies</topic><topic>Antibodies, Viral</topic><topic>Breast</topic><topic>Breast milk</topic><topic>Breastfeeding & lactation</topic><topic>Clinical trials</topic><topic>Colostrum</topic><topic>Confidence intervals</topic><topic>Cord blood</topic><topic>Developing countries</topic><topic>Efficacy</topic><topic>Ethics</topic><topic>Female</topic><topic>Humans</topic><topic>Immune response</topic><topic>Immune system</topic><topic>Immunity</topic><topic>Immunoglobulin A</topic><topic>Immunoglobulin G</topic><topic>Indonesia - epidemiology</topic><topic>Infant</topic><topic>Infants</topic><topic>Laboratories</topic><topic>LDCs</topic><topic>Low income groups</topic><topic>Maternal antibodies</topic><topic>Middle Aged</topic><topic>Milk</topic><topic>Neonates</topic><topic>Placenta</topic><topic>Pregnancy</topic><topic>Questionnaires</topic><topic>Regression analysis</topic><topic>Rotavirus</topic><topic>Rotavirus Infections - prevention & control</topic><topic>Rotavirus Vaccines</topic><topic>Schedules</topic><topic>Vaccine efficacy</topic><topic>Vaccines</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Danchin, Margie H.</creatorcontrib><creatorcontrib>Bines, Julie E.</creatorcontrib><creatorcontrib>Watts, Emma</creatorcontrib><creatorcontrib>Cowley, Daniel</creatorcontrib><creatorcontrib>Pavlic, Daniel</creatorcontrib><creatorcontrib>Lee, Katherine J.</creatorcontrib><creatorcontrib>Huque, Hamidul</creatorcontrib><creatorcontrib>Kirkwood, Carl</creatorcontrib><creatorcontrib>Nirwati, Hera</creatorcontrib><creatorcontrib>At thobari, Jarir</creatorcontrib><creatorcontrib>Dewi Satria, Cahya</creatorcontrib><creatorcontrib>Soenarto, Yati</creatorcontrib><creatorcontrib>Oktaria, Vicka</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Danchin, Margie H.</au><au>Bines, Julie E.</au><au>Watts, Emma</au><au>Cowley, Daniel</au><au>Pavlic, Daniel</au><au>Lee, Katherine J.</au><au>Huque, Hamidul</au><au>Kirkwood, Carl</au><au>Nirwati, Hera</au><au>At thobari, Jarir</au><au>Dewi Satria, Cahya</au><au>Soenarto, Yati</au><au>Oktaria, Vicka</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Rotavirus specific maternal antibodies and immune response to RV3-BB rotavirus vaccine in central java and yogyakarta, Indonesia</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2020-04-03</date><risdate>2020</risdate><volume>38</volume><issue>16</issue><spage>3235</spage><epage>3242</epage><pages>3235-3242</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><abstract>•IgA in breast milk was not associated with reduced RV3-BB vaccine take in Indonesia.•IgG titre in cord blood was associated with lower vaccine immunogenicity after one, not three doses of vaccine.•RV3-BB vaccine appears to be able to be given with breast-feeding in high rotavirus disease burden settings.
Placental or breast milk maternal antibodies can potentially reduce oral rotavirus vaccine efficacy in developing countries. We aimed to examine the relationship between the level of rotavirus specific immunoglobulin A (IgA) and neutralising antibodies (NA) in colostrum and breast milk and cord IgG, with cumulative vaccine take following one and three doses of oral RV3-BB rotavirus vaccine within a Phase IIb trial in Indonesia.
196 infants received three doses of RV3-BB in a randomized, double-blinded trial, using a neonatal schedule (first dose at 0–5 days of age, n = 61), an infant schedule (first dose at ~ 8 weeks of age, n = 67) or placebo (n = 68). Rotavirus specific IgA and NA in colostrum and breast milk, rotavirus specific cord IgG, Serum IgA and stool excretion were measured.
There was little evidence of an association between IgA in colostrum or breast milk and cumulative vaccine take after three doses in the neonatal or infant groups. In the neonatal group, there was a negative association between IgG titre in cord blood and cumulative vaccine take (odds ratio [OR] 0.96; 95% confidence interval [CI] 0.92–1.00; p = 0.03) and serum IgA response (OR 0.94; 95%CI 0.89–0.99; p = 0.02) after one dose of vaccine, which were not evident after three doses in the neonatal or infant groups.
Amongst Indonesian infants we did not find an association between IgA in colostrum or breast milk and vaccine take after 3 doses of RV3-BB vaccine. Maternal rotavirus antibodies in breast milk appear to have minimal impact on RV3-BB vaccine take when administered with a short delay in breast-feeding in settings with a high rotavirus disease burden.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>32160948</pmid><doi>10.1016/j.vaccine.2020.02.087</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0264-410X |
| ispartof | Vaccine, 2020-04, Vol.38 (16), p.3235-3242 |
| issn | 0264-410X 1873-2518 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2376732488 |
| source | MEDLINE; Elsevier ScienceDirect Journals; ProQuest Central UK/Ireland |
| subjects | Aged Antibodies Antibodies, Viral Breast Breast milk Breastfeeding & lactation Clinical trials Colostrum Confidence intervals Cord blood Developing countries Efficacy Ethics Female Humans Immune response Immune system Immunity Immunoglobulin A Immunoglobulin G Indonesia - epidemiology Infant Infants Laboratories LDCs Low income groups Maternal antibodies Middle Aged Milk Neonates Placenta Pregnancy Questionnaires Regression analysis Rotavirus Rotavirus Infections - prevention & control Rotavirus Vaccines Schedules Vaccine efficacy Vaccines Viruses |
| title | Rotavirus specific maternal antibodies and immune response to RV3-BB rotavirus vaccine in central java and yogyakarta, Indonesia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T12%3A38%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Rotavirus%20specific%20maternal%20antibodies%20and%20immune%20response%20to%20RV3-BB%20rotavirus%20vaccine%20in%20central%20java%20and%20yogyakarta,%20Indonesia&rft.jtitle=Vaccine&rft.au=Danchin,%20Margie%20H.&rft.date=2020-04-03&rft.volume=38&rft.issue=16&rft.spage=3235&rft.epage=3242&rft.pages=3235-3242&rft.issn=0264-410X&rft.eissn=1873-2518&rft_id=info:doi/10.1016/j.vaccine.2020.02.087&rft_dat=%3Cproquest_cross%3E2425690885%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2425690885&rft_id=info:pmid/32160948&rft_els_id=S0264410X20303340&rfr_iscdi=true |